ESTRO 2024 - Abstract Book

S1640

Clinical - Lung

ESTRO 2024

121 patients received chemoimmunotherapy and 43 patients not eligible for TRT or PCI were excluded, leaving 78 patients for analysis (median age 65 (42 – 82)). The main reasons for exclusion were mixed response or progression after chemoimmunotherapy and previous radiotherapy to the brain or thorax.

68 patients were eligible for PCI and 69 for TRT.

Of those eligible for PCI, 51/68 (75%) were referred by medical oncologists and 41/51 (80.4%) went on to be offered treatment by clinical oncologists. Out of the 41 patients offered PCI, 9 declined, meaning that only 32 patients went on to receive it. The main reasons for medical oncologists not referring for PCI were patient age and other comorbidities, although in a proportion of cases no reason was documented, 6/17 (35.3%). The reasons for patients not receiving PCI after clinical oncology review are shown in Figure 1.

Of those eligible for TRT, 48/69 (69.6%) were referred by medical oncologists and 30/48 (62.5%) were offered treatment. Out of the 30 patients offered TRT, 3 declined, meaning that only 27 patients went on to receive it. The main reasons for medical oncologists not referring for TRT were a good response in the thorax after chemoimmunotherapy and ongoing toxicity from systemic treatment; 9/21 (42.9%) patients had no documented reason. The reasons for patients not receiving TRT after clinical oncology consultation are shown in Figure 2.

Both PCI and TRT referrals demonstrated variation amongst clinicians, with some consultants referring 80% of their patients while others only 25%.